A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The Independent on MSN
New blood test could show if prostate cancer treatment is failing
New blood test could show if prostate cancer treatment is failing - The discovery could lead to personalised treatments for ...
Dr Hannah McManus looks ahead to the release of new data from phase 3 clinical trials that will inform multidisciplinary ...
BALTIMORE, May 12, 2026 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2026 amendment to the Advanced ...
For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are ...
Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with mCSPC ...
BERLIN -- Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression with the addition of radioligand therapy to hormonal treatment, a ...
Screening for prostate cancer using a blood test likely reduces the risk of dying from prostate cancer and may also reduce the risk of dying from any cause. Screening likely makes little to no ...
A recent abstract published in Nature Communications outlines a new, easy-to-use tool that could help guide early treatment discussions for people with mHSPC. In a nutshell, the innovative system ...
For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...
The FOXA1 protein is a potentially highly sensitive diagnostic marker for small cell carcinoma of the prostate and possibly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results